



Antibiotic Resistance Pattern in *Pseudomonas aeruginosa* Isolated from Clinical Samples Other than Burn Samples in Iran

Ebrahim Karimi¹, Fatemeh Ghalibafan², Akram Esfandani³, Niusha Manoochehri Arash⁴,
Sassan Mohammadi⁴, Azad Khaledi⁵, Hakimeh Akbari^{6*}, and Maria Khurshid^{4*}

1. Emergency Department, Be'sat Hospital, AJA University of Medical Sciences, Tehran, Iran

2. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3. Arak University of Medical Sciences, Arak, Iran

4. Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5. Infectious Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran

6. Cellular and Molecular Research Center, Gerash University of Medical Sciences, Gerash, Iran

Abstract

Background: The purpose of this study was to systematically review the prevalence of class 1 integrons, antibiotic resistance pattern in *Pseudomonas aeruginosa* (*P. aeruginosa*) isolated from clinical samples other than burn samples.

Methods: The Web of Science, PubMed, Scopus, and Science Direct databases were searched using keywords based on the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) guidelines. The cross-sectional studies published from 1st January 2000 until 1st January 2019 were included which addressed the prevalence of class 1 integrons and antibiotic-resistance in *P. aeruginosa* isolated from clinical samples other than burn samples. Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) software. The random-effects model, Cochran's Q and I² tests were applied for statistical analyses.

Results: Eight articles met the eligibility standards for including in the present meta-analysis. The combined prevalence of class 1 integrons in *P. aeruginosa* isolated from clinical samples other than burn samples was reported by 40% (95% CI:26.1-55.8%). The pooled prevalence of Multi-Drug Resistant (MDR) *P. aeruginosa* isolates was 70.1%. The highest prevalence of combined antibiotic resistance was related to carbapenem with a resistance rate of 79.9%. In general, 6 (75%) out of the 8 included studies showed the correlation between the presence of class 1 integrons and antibiotic resistance.

Conclusion: Regarding the correlation between the presence of integrons and the high antibiotic resistance reported by studies included in the present review, there is the need for preventive measures to prevent the spread of resistance by integrons and transferring to other micro-organisms.

Avicenna J Med Biotech 2021; 13(1): 35-41

Keywords: Burns, Drug resistance, Integrons, *Pseudomonas aeruginosa*

Introduction

Pseudomonas aeruginosa (*P. aeruginosa*) is an aerobic non-fermentative gram-negative bacillus and a common nosocomial pathogen. *P. aeruginosa* is one of the dreadful causes of severe infections in clinical settings particularly in immunocompromised patients, as well as individuals hospitalized in Intensive Care Unit (ICU), patients with cystic fibrosis, and those with severe burns¹.

The selective pressure imposed by inappropriate antibiotic use on one hand, and the increasing use of anti-

biotics on the other hand are probably the main causes for the development of Multi-Drug-Resistant (MDR) *P. aeruginosa* in hospital settings².

Infections caused by MDR- *P. aeruginosa* strains present clinically significant challenges. The empiric antibiotic therapy for MDR *P. aeruginosa* has represented poor outcomes with high morbidities, mortalities, long hospital stays and high economic and therapeutic burden on both health systems and the patients³.

According to the reports of the European Centre for

Disease Prevention and Control (ECDC), *P. aeruginosa* comprises 9% of all hospital-based infections presenting the fourth most common hospital pathogen in Europe⁴. Also, CDC reported similar findings in the United States with the frequency about 7% for infections caused by *P. aeruginosa* in hospital settings⁵. A survey in Spain in 2016 showed a higher prevalence about 13% for this microorganism in ICU of hospitals⁶. However, the rate of MDR *P. aeruginosa* isolates in Iran has been reported between 30-100%⁷.

Some possible antimicrobial resistance mechanisms in *P. aeruginosa* include the production of beta-lactamases, overexpression of efflux pumps, down regulation of outer membrane porins, production of AmpC or loss of OprD, genetic mutations, and finally expression of integrons on plasmids and transposons^{4,8}. The integrons are specialized genetic structures by which bacteria can acquire resistance genes through horizontal transmission⁹.

Integrons can acquire external drug resistance gene cassettes and integrate them by site-specific recombination^{10,11}. Generally, integrons are comprised of an integrase gene, two conserved sequences called *sulI* and *int1*, and a variable region harboring gene cassettes between the two conserved fragments¹².

Based on the structure of integrase gene, several classes of integrons have been recognized. Three main classes of integrons (*i.e.* class 1, 2, and 3) have been identified in gram-negative bacteria including *Enterobacteriaceae*, and *Pseudomonas*. Among these, class 1 integrons are the most frequent. Class 1 integrons usually carry one or several gene cassettes conferring resistance to a broad spectrum of antibacterial agents such as β -lactams, aminoglycosides and fluoroquinolones^{13,14}.

Regarding the significance of *P. aeruginosa* in hospital acquired infections, and the lack of a comprehensive study on the prevalence of class 1 integrons in *P. aeruginosa* isolates and antimicrobial resistance patterns of this organism in Iran, an attempt was made to study the prevalence of class 1 integrons, antibiotic resistance pattern in *P. aeruginosa* isolated from clinical samples other than burn samples.

Materials and Methods

Search strategy

The studies addressing the prevalence of class 1 integrons and antibiotic resistance patterns of *P. aeruginosa* isolates from Iranian patients' clinical specimens other than burn samples published from 1st January 2000 till 1st January 2019 were included. The search was carried out in Web of Science, Cochrane Library, Scopus, PubMed, and Google Scholar databases. The search was restricted to the English original articles reporting the prevalence of class 1 integrons in *P. aeruginosa*. The following keywords from medical subject headings or titles or abstracts were used with the help of Boolean operators (AND, OR). "*P. aeruginosa*",

"*P. aeruginosa*", "clinical sample", "clinical specimen", "drug susceptibility", "drug-resistance", "antibiotic resistance", "integrons", "prevalence", "Int1", "Iran", "correlation" and "local studies" were used alone or in combination to conduct a complete search on antibiotic resistance.

Eligibility criteria

All the original articles reporting the prevalence of integrons in *P. aeruginosa* isolated from clinical specimens of Iranian patients were considered. Only those studies that performed antibiotic susceptibility tests based on Clinical and Laboratory Standards Institute (CLSI) guidelines were considered and selected. Foreign studies (*i.e.* not performed in Iran) and those studies that did not follow CLSI guidelines in performing antibiotic susceptibility tests were excluded. Also, all review types were removed. Studies published in languages other than English, articles only available in abstract form and also duplicate publications, letters, case reports and congress abstracts were excluded.

Data extraction

The intended data including first author's name, year of publication, location of study, sample size, the frequencies of MDR and class 1 integrons, hospital wards, and correlation between the presence of integrons and antibiotic resistance were recorded in a data extraction form designed by the researchers.

Qualification of the studies

The strengthening the reporting of observational studies in epidemiology (STROBE) checklist was utilized for qualifying the methodology of the included studies¹⁵. Based on the qualification criteria, the studies were categorized as high, medium or low quality. For quality assessment, a scoring system was used, in which ten questions were designed and for each question one score was considered. If the answer was positive, a score of 1 and if the answer was negative or doubtful, a score of zero was given. Accordingly, the studies were divided into three groups of weak (Score between 1-4), moderate (Score between 5-8) and strong (Score above 8).


Statistical analysis

Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) software (Version 3.3.070). The random-effects model, Cochran's Q and I² tests were applied for statistical analyses. The prevalence of class 1 integrons in *P. aeruginosa* isolates was reported with 95% Confidence Interval (CI). To evaluate possible publication bias, the funnel plot and quantitative Egger weighted regression test were applied. p-value <0.05 was considered a statistically significant cut off for detecting any publication bias.

Results

Inclusion process and characteristics of eligible studies

A total of 911 papers were identified through literature search process (Supplementary figure). Out of



Supplementary figure. Flow chart diagram of selection studies.

these, 456 duplicate studies were recognized and removed. Also, 90 records with irrelevant titles were excluded. The abstracts of 365 remained articles were considered and 259 were excluded owing to justified reasons. Then, 106 full texts of studies were assessed of which, 98 studies were omitted due to either lack of data accessibility, missing data, or not reporting the frequency of class 1 integrons. Finally, 8 articles were included in the quantitative evaluation (Meta-analysis).

As shown in figure 1, the prevalence of class 1 integrons in *P. aeruginosa* isolated from clinical specimens varied from 13.3 to 99.1%. The clinical samples were mostly collected from ICU. The pooled prevalence of MDR *P. aeruginosa* isolates varied from 13.1




Figure 1. Forest plot of the meta-analysis of epidemiology of class 1 integron in *P. aeruginosa* isolated from clinical specimens.

to 100%. Overall, 6 (75 %) out of the 8 included studies in the present review reported the correlation between the presence of class 1 integrons and antibiotic resistance pattern (Table 1, $p < 0.05$).

Overall effects

There was a statistically significant heterogeneity among the included studies ($Q=74.1$, $I^2=90.5$, $t=1.8$, $p=0.12$). Accordingly, the random effects model was applied to combine the prevalence of class 1 integrons in *P. aeruginosa* isolates. The combined prevalence of class 1 integrons was obtained as 40% (95% CI: 26.1-55.8%) in Iranian patients' clinical specimens other than burn samples (Table 2). The pooled prevalence of MDR *P. aeruginosa* isolates was reported as 70.1% (95% CI: 32.6-91.9%).

Publication bias

The publication bias was checked using funnel plot. Concerning possible asymmetrical data distribution in the selected studies, the Egger's linear regression test was used to further evaluate any publication bias. Nevertheless, the results of the Egger's linear regression test revealed no publication bias ($p=0.12$) (Figure 2).

Subgroups analysis

Subgroups analysis revealed that the highest combined antibiotic resistance belonged to carbenicillin following by cloxacillin and cefotaxime with respective resistance rates of 79.9, 77.4, and 76.6%. On the other hand, the most effective antibiotics against *P. aeruginosa* were polymyxin b and colistin with no resistance rate (Figure 3, Table 3).

Table 1. Characteristics of selected studies from Iranian patients

Studies	Publication year	Location	Sample size (N)	MDR N (%)	Int1 in total N (%)	Units	Correlation *
Moradian Kouchaksaraei F, et al (23)	2013	Babol	54	53 (98.1)	20 (37)	ICU	Yes
Aryanezhad M, et al (24)	2016	Bandar Abbas	90	12(13.3)	12(13.3)	ICU, non-ICU	yes
Mohammadzadeh A, et al (36)	2017	Gonabad	95	-	29 (30.5)	Different wards	-
Mobaraki S, et al (2)	2018	Tabriz	200	106(53)	55 (27.5)	Different wards	Yes
Faghri J, et al (18)	2018	Isfahan	72	-	40(55.6)	ICU, non-ICU	Yes
Goli HR, et al (26)	2018	Tabriz	57	57(100)	57(99.1)	ICU	Yes
Pournajaf A, et al (37)	2018	Different	143	12(8.4)	27(18.9)	CF Patient (Iran)	-
Salimizadeh Z, et al (38)	2018	Tehran	21	21(100)	19(90.5)	Different wards	Yes

* Correlation between Int1 and antibiotic resistance, ICU: Intensive care unit, CF: Cystic fibrosis.

Prevalence of Class 1 Integron, Antibiotic Resistance in *P. aeruginosa*

Table 2. Analysis of epidemiology of class 1 integron, and MDRs in *P. aeruginosa* isolated from clinical specimens

Subgroups overall effect	Number of studies	Heterogeneity test			Egger's test		Random model		
		Prevalence (95% CI) (%)	Z	p	Q	p	I ²	T	p
Int1	8	40(26.1-55.8)	1.2	0.00	74.1	0.00	90.5	1.8	0.12
MDR	6	70.1(32.6-91.9)	1	0.00	119.1	0.00	95.8	0.43	0.68

Note: Int1: Class 1 integron; MDR: Multi-drug resistant.




Figure 2. Funnel plot of meta-analysis on the epidemiology of class 1 integron in *P. aeruginosa* isolated from clinical samples.




Figure 3. Antibiotic resistance patterns in *P. aeruginosa* isolated from clinical samples. Imipenem (IPM), Ciprofloxacin (CIP), Gentamicin (GM), Amikacin (AK), Ceftriaxone (CRO), Ceftazidime (CAZ), Cefepime (FEP), Piperacillin/tazobactam (TBZ), Aztreonam (ATM), Cloxacillin (CX), Tobramycin (TOB), Ticarcillin (TIC), Carbenicillin (PY), Cefotaxime (CTX), Norfloxacin (NOR), Polymyxin B (PB), Colistin (CT).

Discussion

In the present study, the combined prevalence of class 1 integrons in *P. aeruginosa* isolates recovered from clinical samples other than burn samples was obtained as 40% ranging from 13.3 to 99.1%. A systematic review and meta-analysis conducted on isolates recovered from Iranian burn samples at similar times showed a higher pooled prevalence of class 1 integrons in *P. aeruginosa* (69%) compared to the present review¹⁶.

Seventy-five percent of the included studies in the current review described a correlation between the presence of class 1 integrons and antibiotic resistance. Similarly, a significant correlation was found between the presence of class 1 integrons and antibiotic resistance in 55.5% of studies selected for review on burn samples from Iran¹⁶.

This is while most of *P. aeruginosa* isolates repre-

sented the high resistance toward carbenicillin, and cloxacillin. Polymyxin B and colistin are among the most important anti-pseudomonal antibiotics with the highest effects against MDR *P. aeruginosa* isolates. Likely, a review conducted on burn samples from Iran at the similar time¹⁶ and also another study from North of Iran (Guilan)¹⁷ showed the same pattern, as the highest combined resistance was reported against cloxacillin, followed by carbenicillin and ceftriaxone. There was no difference between antibiotic resistance pattern, MDR isolates, and prevalence of integrons in isolates recovered from both burn and non-burn samples, while these parameters were high in either of them which can be considered by clinicians and physicians.

The noticeable differences and variability in the distribution of class 1 integrons among the Iranian studies included in the current systematic review and meta-analysis may be partly due to the heterogeneities in the patterns of antibiotics use, as well as the sources of infections and geographical locations¹⁸. Integrons carrying gene cassettes provide a powerful vehicle for the fast horizontal transmission of antibiotic resistance genes among different bacterial populations, and in this manner, contribute to the dissemination of antibiotic resistance in hospital settings which creates a serious concern for human health services⁹. Similar to our findings, several researchers such as Ren *et al.* in the United States¹⁹, Cholley *et al.* in France²⁰, and Taccone *et al.* in Brooklyn²¹ have reported a relationship between the expression of class 1 integrons and antibiotic resistance in bacterial strains. In accordance with our findings, the class 1 integrons have been reported as the most common integrons expressed in *P. aeruginosa* isolates in studies conducted in Japan²², Spain⁹, and China¹⁰.

The high frequency of integrons particularly class 1 integrons among resistant *P. aeruginosa* isolates highlights a role for these genetic elements in resistance to antimicrobial agents. In this study, relatively high rates of resistant *P. aeruginosa* in ICU and other units of hospitals were reported, and also patients in these units were particularly susceptible to infections caused by MDR *P. aeruginosa*. Thus, particular strategies should be implemented to prevent the colonization of gram-negative bacteria such as *P. aeruginosa* and transmission of resistance genes among these micro-organisms through integrons in hospital settings²³.

A study carried out by Aryanezhad *et al.*²⁴, included in the present review, showed a significant correlation between antibiotic resistance pattern and the presence

Table 3. Subgroups analysis for antibiotic resistance in *P. aeruginosa* isolated from clinical samples other than burn samples

Subgroups	Number of studies	Heterogeneity test			Egger's test		Random model		
		Prevalence (95% CI) (%)	Z	P	Q	P	I ²	T	p
Imipenem	7	47.5(32.8-62.7)	0.31	0.00	352.6	0.42	96.3	0.83	0.75
Ciprofloxacin	8	62.4(48.6-74.5)	1.7	0.00	406.7	0.2	96.06	1.1	0.07
Gentamicin	7	60.5(47.4-72.2)	1.5	0.11	288.9	0.37	95.1	0.9	0.11
Amikacin	8	57.4(46.4-67.8)	1.3	0.00	262.2	0.9	94.2	0.1	0.18
Ceftriaxone	5	58.6(29.8-82.5)	0.56	0.00	129.8	0.72	96.9	0.37	0.57
Ceftazidime	6	57.8(44.4-70.2)	1.14	0.00	289.6	0.99	95.5	0.00	0.25
Cefepime	5	46.4(26.6-67.4)	0.32	0.00	250.9	0.34	96.8	1	0.74
Piperacillin/tazobactam	6	50.6(40.4-60.8)	0.11	0.00	102.9	0.35	91.2	0.97	0.9
Aztreonam	5	48.1(27.9-68.9)	0.17	0.00	180.7	0.1	96.6	1.9	0.86
Cloxacillin	3	77.4(62.8-87.4)	3.4	0.00	32.8	0.23	90.8	1.6	0.001
Tobramycin	6	65.8(51.2-77.9)	2.1	0.00	160.8	0.78	95	0.28	0.035
Ticarcillin	8	55.4(40.1-69.7)	0.68	0.00	102.5	0.70	93.1	0.39	0.49
Carbenicillin	3	79.9(72.7-85.6)	6.7	0.00	2.7	0.80	28.3	0.32	0.00
Cefotaxime	3	76.6(72.1-80.6)	9.7	0.00	9.6	0.96	79.3	0.05	0.00
Norfloxacin	4	57.3(11.5-93.3)	0.24	0.00	180.9	0.45	98.3	0.91	0.81
Polymyxin B	3	1(1-2.5)	6.4	0.00	0.001	0.05	0.00	121	0.00
Colistin	3	1(1-1.25)	4.1	0.00	0.001	0.06	0.00	102	0.00

Note: CI: Confidence interval, Q: Cochran's Q test, P: p value, T: t student test, I²: I-square, Z: Z-value.

of integron class 1 among isolates recovered from ICU's patients compared to ones retrieved from other wards. The resistance to third generation of cephalosporins, carbapenems, aminoglycosides, and aminopenicillins was possibly caused by integron class 1, leading to clonal spread of these resistance genes in different hospital units and consequently among patients hospitalized in clinical settings²⁵. Also, similar to other studies mentioned in the present review, a high level of resistance in positive isolates for class 1 and 2 integrons was observed against ceftazidime and ciprofloxacin, with prevalence rate of 82.5, and 76.2%, respectively in a study conducted by Faghri *et al*¹⁸. Interestingly, they reported a significant correlation between presence of class 1 and 2 integrons and the high antibiotic resistance¹⁸. For further confirming the role of integrons in antibiotic resistance, another study conducted by Goli *et al* described the significant relationship between the presence of class 1 integrons and resistance against aminoglycosides and beta-lactams. Moreover, they reported that all burn isolates were integron-positive and MDR²⁶.

Nevertheless, some included studies showed no relationship between the presence of integrons and antibiotic resistance in *P. aeruginosa*. This may partially be related to the contribution of other mechanisms involved in antibiotic resistance such as the overexpression of AmpC beta lactamase (which is encoded by chromosomal genome), the repression or inactivation of Carbapenem porin OprD, and the up-regulation of different efflux pumps⁴.

In the present review, the pooled prevalence of MDR *P. aeruginosa* isolates recovered from clinical specimens of Iranian patients was 70.1%. In comparison, the frequency of MDR *P. aeruginosa* isolates was

reported 30% in eastern European countries²⁷ that was lower than the ratio obtained here. In line with our findings, however, other studies in China²⁸ and Brazil²⁹ reported the high frequency of MDR *P. aeruginosa* isolates. In accordance with our results, Fonseca *et al* showed that more than half of imipenem-resistant and almost all MDR *P. aeruginosa* isolates expressed class 1 integrons²⁹.

In the current study, the most effective antibiotics against *P. aeruginosa* isolates were polymyxin B and colistin with susceptibility rate of 100%. This is while most of *P. aeruginosa* isolates represented the high resistance toward carbenicillin (79.9%), cloxacillin (77.4%), and cefotaxime (76.6%). Polymyxin B and colistin are among the most important anti-pseudomonal antibiotics with the highest effects against MDR *P. aeruginosa* isolates. However, both of these antibiotics have been associated with side effects and toxicities⁴. In fact, the restricted prescription of polymyxins because of their toxicity is probably the most important reason for the high susceptibility rate (100%) of *P. aeruginosa* isolates in exposure to these antibiotics³⁰. Accordingly, a report from Spain in 2015 revealed a high rate of combined resistance to three or more frequently prescribed antimicrobial agents (Piperacillin-tazobactam, ceftazidime, fluoroquinolones, aminoglycosides and carbapenems) among *P. aeruginosa* isolates³¹. Also, polymyxins have shown the highest antibacterial activity among XDR *P. aeruginosa* isolates²⁷ which is in agreement with our results.

To the best of our knowledge, fluoroquinolones (such as ciprofloxacin) are among the most effective available antibiotics for the treatment of *P. aeruginosa* infections, particularly urinary tract infections³². In this study, however, up to 50% of *P. aeruginosa* iso-

lates showed the resistance against ciprofloxacin. According to the studies conducted in Latin America and Europe, 25-30% of *P. aeruginosa* isolates were also resistant to ciprofloxacin^{33,34}. In addition, in this study, a broad resistance against beta-lactams and aminoglycosides was observed in *P. aeruginosa* strains which is in line with the results of previous studies^{28,35}. On the contrary, other researchers have described low resistance rates of *P. aeruginosa* against aminoglycosides^{23,29}. Overall, the prevalence of MDR *P. aeruginosa* isolates was high in clinical samples other than burn samples obtained from Iranian patients especially those hospitalized in critical care units. Furthermore, a high penetrance of class 1 integrons was noted in the MDR *P. aeruginosa* isolates delineating their association with antibiotic resistance in these bacteria. Timely reporting of antibiotic resistance patterns in these bacteria is recommended to prescribe appropriate antibiotics. Also, it is recommended to develop hospital-based infection control committees and educate their members regarding the nosocomial infections control programs. The current review showed the polymyxin B and colistin as the effective antibiotics; however, the toxic adverse effects are seen in cases treated with polymyxins.

As it is clear from the results, the *Pseudomonas* strains showed more than 50% resistance against most antibiotics, which indicates an increase in resistance against *P. aeruginosa* in Iran. Gradually, special antibiotics will not be available to treat *Pseudomonas* infections and there is a serious challenge for the control of infections created by *Pseudomonas*. Furthermore, the high prevalence of class 1 integrons and consequently the higher prevalence of MDR strains show the significant role that class 1 integrons play in the transmission of antibiotic resistance, which has become a serious problem for health systems in our country that should be seriously considered.

Conclusion

Results of the present review indicate a high rate of antibiotic resistance among *P. aeruginosa* isolates recovered from clinical samples. Also, 70% of isolates were MDR and the prevalence of class 1 integrons was almost high. These integrons had genes for resistance to different family members of antibiotics and caused multi drug resistance in our isolates. A significant correlation between the presence of integrons and the high antibiotic resistance was reported by most studies included in the present review. Therefore, existence of class 1 integrons shows high risk of resistance transmission and spreading of MDR isolates in clinical settings. Antibiotic consumption control and antibiotic stewardship are required for decreasing resistance in clinical strains. There is a necessity for preventive measures (safe food preparation, immunization, hand washing, and taking antibiotics as directed and only

when needed) to prevent the spread of these resistances by integrons and transferring to other micro-organisms.

Conflict of Interest

None declared.

References

1. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen–host interactions in *Pseudomonas aeruginosa* pneumonia. *Am J Respir Crit Care Med* 2005;171(11):1209-23.
2. Mobaraki S, Aghazadeh M, Barhaghi MHS, Memar MY, Goli HR, Gholizadeh P, et al. Prevalence of integrons 1, 2, 3 associated with antibiotic resistance in *Pseudomonas aeruginosa* isolates from Northwest of Iran. *BioMedicine* 2018;8(1):2.
3. Haidar G, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant *Pseudomonas aeruginosa* infections: clinical effectiveness and evolution of resistance. *Clin Infect Dis* 2017;65(1):110-20.
4. Ruiz-Garbajosa P, Canton R. Epidemiology of antibiotic resistance in *Pseudomonas aeruginosa*. Implications for empiric and definitive therapy. *Rev Esp Quimioter* 2017;30(Suppl 1):8-12.
5. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate point-prevalence survey of health care–associated infections. *New Engl J Med* 2014;370(13):1198-208.
6. Palomar M, Álvarez-Lerma F, Olaechea P, Insausti J, López-Pueyo M. Estudio nacional de vigilancia de infección nosocomial en servicios de medicina intensiva. SEMICYUC.[Consultado el 10 dic 2014] Disponible en: URL: [http://hws.vhebron.net/envin-helics/Help/Informe % 20ENVIN-UCI 202012](http://hws.vhebron.net/envin-helics/Help/Informe%20ENVIN-UCI202012).
7. Vaez H, Salehi-Abargouei A, Ghalehnoo ZR, Khademi F. Multidrug resistant *Pseudomonas aeruginosa* in Iran: A systematic review and metaanalysis. *J Glob Infect Dis* 2018;10(4):212-17.
8. Carattoli A. Importance of integrons in the diffusion of resistance. *Veterinary Res* 2001;32(3-4):243-59.
9. Ruiz-Martínez L, López-Jiménez L, Fusté E, Vinuesa T, Martínez J, Viñas M. Class 1 integrons in environmental and clinical isolates of *Pseudomonas aeruginosa*. *Int J Antimicrob Agents* 2011;38(5):398-402.
10. Gu B, Tong M, Zhao W, Liu G, Ning M, Pan S, et al. Prevalence and characterization of class I integrons among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolates from patients in Nanjing, China. *J Clin Microbiol* 2007;45(1):241-3.
11. Mazel D, Dychinco B, Webb VA, Davies J. Antibiotic resistance in the ECOR collection: integrons and identification of a novel aad gene. *Antimicrob Agents Chemother* 2000;44(6):1568-74.
12. Gillings MR, Gaze WH, Pruden A, Smalla K, Tiedje JM, Zhu YG. Using the class 1 integron-integrase gene as a proxy for anthropogenic pollution. *ISME J* 2015;9(6):1269-79.

13. Deng Y, Bao X, Ji L, Chen L, Liu J, Miao J, et al. Resistance integrons: class 1, 2 and 3 integrons. *Ann Clin Microbiol Antimicrob* 2015;14(1):45.
14. Hall RM, Collis CM. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. *Drug Resist Updat* 1998;1(2):109-19.
15. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Int J Surg* 2014;12(12):1500-24.
16. Heidarzadeh S, Enayati Kaliji Y, Pourpaknia R, Mohammadzadeh A, Ghazali-Bina M, Saburi E, et al. A meta-analysis of the prevalence of class 1 integron and correlation with antibiotic resistance in *Pseudomonas aeruginosa* recovered from Iranian burn patients. *J Burn Care Res* 2019;40(6):972-8.
17. Nikokar I, Tishayar A, Flakiyan Z, Alijani K, Rehana-Banisaeed S, Hossinpour M, et al. Antibiotic resistance and frequency of class 1 integrons among *Pseudomonas aeruginosa*, isolated from burn patients in Guilan, Iran. *Iran J Microbiol* 2013;5(1):36-41.
18. Faghri J, Nouri S, Jalalifar S, Zalipoor M, Halaji M. Investigation of antimicrobial susceptibility, class I and II integrons among *Pseudomonas aeruginosa* isolates from hospitalized patients in Isfahan, Iran. *BMC Res Notes* 2018;11(1):806.
19. Ren CL, Konstan MW, Yegin A, Rasouliyan L, Trzaskoma B, Morgan WJ, et al. Multiple antibiotic-resistant *Pseudomonas aeruginosa* and lung function decline in patients with cystic fibrosis. *J Cystic Fibros* 2012;11(4):293-9.
20. Cholley P, Thouverez M, Hocquet D, Van Der Mee-Marquet N, Talon D, Bertrand X. Most multidrug-resistant *Pseudomonas aeruginosa* isolates from hospitals in eastern France belong to a few clonal types. *J Clin Microbiol* 2011;49(7):2578-83.
21. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant *Pseudomonas aeruginosa* septic shock. *Antimicrob Agents Chemother* 2012;56(4):2129-31.
22. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, et al. PCR typing of genetic determinants for metallo- β -lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. *J Clin Microbiol* 2003;41(12):5407-13.
23. Moradian Kouchaksaraei F, Shahandashti EF, Molana Z, Moradian Kouchaksaraei M, Asgharpour F, Mojtahedi A, et al. Molecular detection of Integron genes and pattern of antibiotic resistance in *Pseudomonas aeruginosa* strains isolated from intensive care unit, Shahid Beheshti Hospital, North of Iran. *Int J Mol Cell Med* 2012;1(4):209-17.
24. Aryanezhad M, Shakibaie MR, Karmostaji A, Shakibaie S. Prevalence of Class 1, 2, and 3 Integrons and Biofilm Formation in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* among ICU and non-ICU Patients. *Infect Epidemiol Med* 2016;2(4):1-7.
25. Jabbari Amiri MR, Siami R, Khaledi A. Tuberculosis status and coinfection of pulmonary fungal infections in patients referred to reference laboratory of health centers Ghaemshahr city during 2007-2017. *Ethiop J Health Sci* 2018;28(6):683-90.
26. Goli HR, Nahaei MR, Rezaee MA, Hasani A, Kafil HS, Aghazadeh M, et al. Role of MexAB-OprM and MexXY-OprM efflux pumps and class 1 integrons in resistance to antibiotics in burn and Intensive Care Unit isolates of *Pseudomonas aeruginosa*. *J Infect Public Health* 2018;11(3):364-72.
27. Oliver A, Mulet X, Lopez-Causape C, Juan C. The increasing threat of *Pseudomonas aeruginosa* high-risk clones. *Drug Resist Updat* 2015;21-22:41-59.
28. Chen J, Su Z, Liu Y, Wang S, Dai X, Li Y, et al. Identification and characterization of class 1 integrons among *Pseudomonas aeruginosa* isolates from patients in Zhenjiang, China. *Int J Infect Dis* 2009;13(6):717-21.
29. Fonseca ÉL, Vieira VV, Cipriano R, Vicente AC. Class 1 integrons in *Pseudomonas aeruginosa* isolates from clinical settings in Amazon region, Brazil. *FEMS Immunol Med Microbiol* 2005;44(3):303-9.
30. Fernández L, Álvarez-Ortega C, Wiegand I, Olivares J, Kocíncová D, Lam JS, et al. Characterization of the polymyxin B resistance of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* 2013;57(1):110-9.
31. Gelband H, Miller-Petrie M, Pant S, Gandra S, Levinson J, Barter D, et al. The state of the world's antibiotics 2015. Center for Disease Dynamics, Economics & Policy 2015. CDDEP: Washington, D.C.
32. Gales A, Jones R, Turnidge J, Rennie R, Ramphal R. Characterization of *Pseudomonas aeruginosa* isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis* 2001;32(Supplement_2):S146-S155.
33. Bouza E, Garcia-Garrote F, Cercenado E, Marin M, Diaz M. *Pseudomonas aeruginosa*: a survey of resistance in 136 hospitals in Spain. *Antimicrob Agents Chemother* 1999;43(4):981-2.
34. Brown PD, Izundu A. Antibiotic resistance in clinical isolates of *Pseudomonas aeruginosa* in Jamaica. *Rev Panam Salud Publica* 2004;16(2):125-30.
35. Poonsuk K, Tribuddharat C, Chuanchuen R. 2012. Class 1 integrons in *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolated from clinical isolates. *Southeast Asian J Trop Med Public Health* 2012;43(2):376-84.
36. Mohammadzadeh A, Mardaneh J, Ahmadi R, Adabi J. Evaluation of the virulence features and antibiotic resistance patterns of pathogenic *Pseudomonas aeruginosa* strains isolated from hospitalized patients in Gonabad, Iran. *Arch Pediatr Infect Dis* 2017;5(3): e41267.
37. Pournajaf A, Razavi S, Irajian G, Ardebili A, Erfani Y, Solgi S, et al. Kafshgari, R. 2018. Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis *Pseudomonas aeruginosa* isolates. *Infez Med* 2018;26(3):226-36.
38. Salimizadeh Z, Karoui H, Masoud S, Hosseini F. Dissemination of Class 1 integron among different multidrug resistant *Pseudomonas aeruginosa* strains. *Medical Laboratory Journal* 2018;12(4):36-42.